Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 100%High 0 · 0%

SGLT2 inhibitors vs placebo

Diabetic ketoacidosis median · people with diabetes and CKD

Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors probably leads to higher diabetic ketoacidosis median compared with placebo (moderate certainty).

1 finding from 1 review

Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes 2024 · Cochrane Headline outcomes only
RR 2.05 [1.34, 3.14]
13 studies · 38710 participants
Moderate